Increased Survival From Stage IV Melanoma Associated With Fewer Regulatory T Cells

Journal of Surgical Research

Volumn 154, Issue 1, 2009, Pages 13-20

  Baumgartner, Joel M ^a   Gonzalez, Rene ^a   Lewis, Karl D ^a   Robinson, William A ^a   Richter, Don A ^a   Palmer, Brent E ^a   Wilson, Cara C ^a   McCarter, Martin D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

dendritic cell; melanoma; regulatory T cell; survival

Indexed keywords

CD123 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; MEDICAL RECORD; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; SURVIVAL TIME;

ANTIGENS, CD; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; MELANOMA; SURVIVAL RATE; SURVIVORS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 67349182310     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.04.043     Document Type: Article

References (29)

1. Eggermont A.M. Randomized trials in melanoma: An update. Surg Oncol Clin North Am 15 (2006) 439
2. Riker A.I., Radfar S., Liu S., et al. Immunotherapy of melanoma: A critical review of current concepts and future strategies. Expert Opin Biol Ther 7 (2007) 345
3. Geertsen R., Hofbauer G., Kamarashev J., et al. Immune escape mechanisms in malignant melanoma. Int J Mol Med 3 (1999) 49
4. Gajewski T.F., Meng Y., and Harlin H. Immune suppression in the tumor microenvironment. J Immunother 29 (2006) 233
5. Enk A.H., Jonuleit H., Saloga J., et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73 (1997) 309
6. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767
7. Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat Rev 4 (2004) 941
8. Rissoan M.C., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science (New York) 283 (1999) 1183
9. Cox K., North M., Burke M., et al. Plasmacytoid dendritic cells (PDC) are the major DC subset innately producing cytokines in human lymph nodes. J Leukoc Biol 78 (2005) 1142
10. Gilliet M., and Liu Y.J. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 63 (2002) 1149
11. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345
12. Ziegler S.F. FOXP3: Of mice and men. Annu Rev Immunol 24 (2006) 209
13. Wolf A.M., Wolf D., Steurer M., et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9 (2003) 606
14. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Investig 117 (2007) 1167
15. Viguier M., Lemaitre F., Verola O., et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173 (2004) 1444
16. McCarter M.D., Baumgartner J., Escobar G.A., et al. Immunosuppressive dendritic and regulatory T cells are up-regulated in melanoma patients. Ann Surg Oncol 14 (2007) 2854
17. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942
18. Bates G.J., Fox S.B., Han C., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 (2006) 5373
19. Kobayashi N., Hiraoka N., Yamagami W., et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13 (2007) 902
20. Griffiths R.W., Elkord E., Gilham D.E., et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 56 (2007) 1743
21. Alvaro T., Lejeune M., Salvado M.T., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11 (2005) 1467
22. Carreras J., Lopez-Guillermo A., Fox B.C., et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108 (2006) 2957
23. Saleh F., Renno W., Klepacek I., et al. Direct evidence on the immune-mediated spontaneous regression of human cancer: An incentive for pharmaceutical companies to develop a novel anticancer vaccine. Curr Pharm Design 11 (2005) 3531
24. Frumento G., Piazza T., Di Carlo E., et al. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 6 (2006) 233
25. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev 2 (2002) 151
26. Vermi W., Bonecchi R., Facchetti F., et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200 (2003) 255
27. Perrot I., Blanchard D., Freymond N., et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178 (2007) 2763
28. Manola J., Atkins M., Ibrahim J., et al. Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18 (2000) 3782
29. Roncador G., Brown P.J., Maestre L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 35 (2005) 1681